Adaptive AI systems in medical devices and digital health solutions challenge long‑standing liability principles. Unlike static software, continuous‑learning algorithms evolve after market entry, raising complex questions about design defect, foreseeability, and post-market obligations. Courts and regulators vary in their interpretation of liability when updates alter performance, and whether manufacturers bear an ongoing duty to monitor, validate, and warn. Key focus areas include evidence preservation, version control, audit logs, and explainability, as well as contractual safeguards for algorithm drift and shared responsibilities among manufacturers, developers, integrators, and distributors.

At the center of the evolving regulatory landscape that addresses these questions for the EU are the revised Product Liability Directive (PLD), the MDR/IVDR, and the AI Act (AIA). The PLD's novel procedural mechanisms include rights of access to evidence and presumptions of defectiveness and causation, its concept of software as a product, its extended definition of product defect, and its recognition of system interconnectedness will significantly affect claims involving continuous‑learning models. At the same time, MDR/IVDR obligations regarding post market surveillance, performance stability, and update governance play a pivotal role in shaping what courts may view as reasonable manufacturer conduct. Even proposed AIA exemptions for medical devices do not eliminate the influence of AI‑specific concepts, such as data governance, transparency, and human oversight.

From a litigation perspective, adaptive AI amplifies the challenge of reconstructing causation, and it heightens the importance of rigorous documentation. As updates alter system functionality, parties may struggle to determine whether harm resulted from an original design defect, a post market modification, an external data drift, or clinical misuse. Courts are likely to scrutinize whether manufacturers maintained sufficient version control, audit logs, and explainability artifacts. This goes hand in hand with litigation requiring proof of lifecycle governance, not merely proof of conformity, at the time of market entry.

Given these trends, contractual risk allocation is increasingly a key tool for managing exposure across the AI supply chain. Agreements between developers, integrators, distributors, and health care operators should clearly delineate responsibilities to prevent uncertainty regarding who must act when system behavior evolves. In an environment where AI never stands still, litigation readiness depends on embedding resilience into governance frameworks. Organizations that implement end‑to‑end documentation, transparent change‑management structures, proactive monitoring, and coordinated contractual safeguards will be best positioned to defend claims and demonstrate responsible stewardship of adaptive medical AI.